EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Precision medicine in AML: overcoming resistance

Samuel Urrutia, Koichi Takahashi

International Journal of Hematology · 2024

DOI: 10.1007/s12185-024-03827-8 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Hematology, 2024. Verfasst von Samuel Urrutia und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, 1901 East Road, 4SCR6.2085, Houston, TX, 77030-4009, USA. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Precision Medicine, Drug Resistance, Neoplasm, Molecular Targeted Therapy. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 114 Literaturangaben. Gefördert von: Leukemia and Lymphoma Society, Break Through Cancer, Conquer Cancer Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The development of molecularly targeted therapy for acute myeloid leukemia is progressing at an accelerated pace. Therapies targeting FLT3, IDH1, IDH2, and BCL2 have been approved in the last 5 years. As we exploit these biological vulnerabilities, various mechanisms of resistance arise. Emergence of competing clones with different genetic drivers and acquisition of constitutional mutations in the target renders therapies ineffective, and enzymatic isoform changes can lead to reappearance of the disease phenotype. Understanding the timing and circumstances of resistance origination will allow clinicians to develop combinatorial and sequential therapeutic approaches to deepen responses and improve survival. The objective of this review is to illustrate the biological underpinnings of each therapy and the landscape of resistance mechanisms and discuss strategies to overcome on- and off-target resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcutePrecision MedicineDrug Resistance, NeoplasmMolecular Targeted TherapyMutationHumansIsocitrate Dehydrogenasefms-Like Tyrosine Kinase 3Proto-Oncogene Proteins c-bcl-2

Stichwörter der Autor:innen

Acute myeloid leukemiaResistance mechanismsTargeted therapy

Substanzen

Isocitrate Dehydrogenasefms-Like Tyrosine Kinase 3IDH2 protein, humanProto-Oncogene Proteins c-bcl-2FLT3 protein, humanIDH1 protein, human

Autor:innen und Institutionen

  • Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, 1901 East Road, 4SCR6.2085, Houston, TX, 77030-4009, USA.
  • Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, USA. ktakahashi@mdanderson.org.

Förderung

  • Leukemia and Lymphoma Society
  • Break Through Cancer
  • Conquer Cancer Foundation

Zitieren

APA

Urrutia, S., & Takahashi, K. (2024). Precision medicine in AML: overcoming resistance. International Journal of Hematology. https://doi.org/10.1007/s12185-024-03827-8

Vancouver

Urrutia S, Takahashi K. Precision medicine in AML: overcoming resistance. International Journal of Hematology. 2024. doi:10.1007/s12185-024-03827-8

BibTeX
@article{Urrutia2024,
  author = {Urrutia, Samuel and Takahashi, Koichi},
  title = {Precision medicine in AML: overcoming resistance},
  journal = {International Journal of Hematology},
  year = {2024},
  doi = {10.1007/s12185-024-03827-8}
}
Kostenlos starten →